... 2Research articlePersistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics RegisterAmr A ... (CEO of the British Society for Rheumatology) , Mervyn Hogg and members of the BSRBR Scientific Steering Committee. The authors also acknowledge the seminal role of the British Society for Rheumatology ... drawn.Firstly, infliximab was the first anti-TNF drug to be marketedand, during the early years of this study, more patients werereceiving infliximab as their first anti-TNF therapy, despite the drug...